publication date: Aug. 4, 2017
NETRF announces grants for neuroendocrine cancer research
The Neuroendocrine Tumor Research Foundation announced a new round of scientific and clinical research grants, aimed at advancing the treatment of and the search for cures to neuroendocrine tumors.
The grants, which would take effect in 2018, fall into three categories: Accelerator Grants, Investigator Grants, and Pilot Project Grants. Made possible in part by a gift from the Margie and Robert E. Petersen Foundation, the grants vary from $50,000 to $1.2 million and run up to four years.
“These are significant grants meant to transform our progress and continue our commitment to attract and support a committed community of investigators dedicated to a cure,” said Ron Hollander, NETRF executive director.
“We are looking to attract the best ideas and the brightest researchers and physicians whose work can have a rapid impact on improving care for NET patients.”
NETRF uses a rigorous peer process that includes external expert reviewers and a board of scientific advisors.
Applicants must submit a letter of intent by Sept. 5.
From that pool, investigators will be invited to submit full proposals. Grant awards will be announced in early 2018.
“We are seeking cutting-edge research proposals that apply novel science and new technologies to help advance existing knowledge and accelerate the development of diagnostic and therapeutic interventions for patients,” said Effie Tzameli, NETRF director of research.
In April 2017, NETRF announced $4 million in collaborative research grants to expand the molecular understanding of NETs and help drive personalized treatment options for patients. These ongoing projects use genomic sequencing, gene editing, and bioengineering to look for actionable targets for treatment.
“In our 2017 grants, we focused on funding teams that could help us unlock the biologic and genomic drivers … Continue reading NETRF announces grants for neuroendocrine cancer research
To access this members-only content, please log in.
Institutional subscribers, please log in with your IP
If you're not a subscriber why not join today?
To gain access to the members only content click here
You will be given immediate access to premium content on the site.Click here to join.